Archive for the ‘oncology retractions’ Category
The Office of Research Integrity (ORI) has ruled in a case we’ve been following for nearly two years — and which seems to have been launched after Retraction Watch readers took a careful look at figures from what appeared to be an unrelated case.
Takao Takahashi and Makato Suzuki, both former postdocs at a cancer research center at UT-Southwestern, both “knowingly, intentionally, and recklessly falsified data” in a total of 10 papers, according to the ORI. Takahashi, now at Gifu University in Japan, was responsible for fakery in four papers, while Suzuki, now at Kumamoto University Hospital, also in Japan, falsified data in six.
We reported on the retraction of the four Takahashi papers, and one of the Suzuki papers, in November 2012. At that time, Adi Gazdar, the head of the lab where the researchers worked, told us that
Read the rest of this entry »
A few weeks after the paper was published on June 9, comments on PubPeer began accumulating. Commenters called out both potentially manipulated and repeated images. The exact timeline is not clear, because Oncogene does not list a date on the retraction notice, but by August 29 the paper had been retracted.
Here’s the notice for “IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer,” by researchers at Shanghai Jiaotong University School of Medicine and Ruijin Hospital, both in Shanghai, China, and the University of Michigan: Read the rest of this entry »
The authors of a letter replying to a comment in a urology journal have retracted their response because it contained inappropriate figures. At least, that’s the official story.
The original paper, “Effect of a Risk-stratified Grade of Nerve-sparing Technique on Early Return of Continence After Robot-assisted Laparoscopic Radical Prostatectomy,” came from a group at Weill Medical College of Cornell University led by Ashutosh Tewari. Published in July 2012 in European Urology, it purported to find that: Read the rest of this entry »
A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).
Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:
A paper about a protein being used — unapproved by health agencies — to treat diseases including cancer and autism has been retracted.